[HTML][HTML] A mini review of novel topoisomerase II inhibitors as future anticancer agents

CO Okoro, TH Fatoki - International journal of molecular sciences, 2023 - mdpi.com
Several reviews of inhibitors of topoisomerase II have been published, covering research
before 2018. Therefore, this review is focused primarily on more recent publications with …

DNA intercalators as anticancer agents

S Venugopal, V Sharma, A Mehra… - Chemical biology & …, 2022 - Wiley Online Library
Cancer is one of the most prevailing disease conditions, which occurs due to uncontrolled
cell division either due to natural mutation to the genes or due to changes induced by …

Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation

K El-Adl, HM Sakr, RG Yousef, ABM Mehany… - Bioorganic …, 2021 - Elsevier
VEGF/VEGFR2 pathway is the crucial therapeutic target in the treatment of cancer. So that, a
new series of quinoxaline-2 (1H)-one derivatives were designed and synthesized. The …

Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers

MM Alanazi, IH Eissa, NA Alsaif… - Journal of Enzyme …, 2021 - Taylor & Francis
Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in cancer
angiogenesis. Inhibition of VEGFR-2 activity proved effective suppression of tumour …

Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and …

AA Al-Karmalawy, M Rashed, M Sharaky… - European Journal of …, 2023 - Elsevier
Although the great effectiveness of doxorubicin (Dox) in the treatment of many types of
tumors, it showed limited effectiveness against the head and neck squamous cell carcinoma …

Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies

RG Yousef, A Elwan, IMM Gobaara… - Journal of Enzyme …, 2022 - Taylor & Francis
Abstract New nicotinamide derivatives 6, 7, 10, and 11 were designed and synthesised
based on the essential features of the VEGFR-2 inhibitors. Compound 10 revealed the …

Nanogel-mediated drug delivery system for anticancer agent: pH stimuli responsive poly (ethylene glycol/acrylic acid) nanogel prepared by gamma irradiation

NEA Abd El-Sattar, SESA El-Hddad, MM Ghobashy… - Bioorganic …, 2022 - Elsevier
The popularity of nanogel as nano drug carrier lies in its adjustable physical properties, and
the ability to encapsulate drug particles with improved properties is being developed to meet …

[HTML][HTML] Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2, 4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR T790M …

NAAM Aziz, RF George, K El-Adl, WR Mahmoud - RSC advances, 2022 - pubs.rsc.org
Fourteen recent thiazolidine-2, 4-diones bearing furan and/or thiophene heterocyclic rings
have been designed, synthesized and assessed for their anticancer activities against four …

Design, synthesis, molecular docking and in silico ADMET profile of pyrano [2, 3-d] pyrimidine derivatives as antimicrobial and anticancer agents

NEA Abd El-Sattar, K El‐Adl, MA El-Hashash… - Bioorganic …, 2021 - Elsevier
Abstract Pyrano [2, 3-d] pyrimidine derivatives were synthesized by treating cyclic
compounds containing active methylene group with aldehyde and malononitrile in butanol …

Exploration of thiazolidine‐2, 4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations

NAAM Aziz, RF George, K El‐Adl… - Archiv der …, 2023 - Wiley Online Library
As dual EGFR and VEGFR‐2 inhibitors, 22 innovative thiazolidine‐2, 4‐diones were
modeled, constructed, and measured for their anticancer performance versus four human …